Andy Studna, Senior Editor

Global, multicenter, randomized, open-label, parallel-group study will evaluate ABBV-383 in adult patients with relapsed/refractory multiple myeloma.

Results from new analysis show RYBREVANT plus lazertinib consistently and significantly improved progression-free survival compared to osimertinib.

Under the new extension, FDA and CluePoints will enhance CluePoints’ SMART software to address a broader range of regulatory concerns.

In the third and final part of this video interview, Sam Liu, VP of marketing, Vivalink looks forward in the BYOD space and forecasts potential advancements for consumer devices.

Results showed non-inferior efficacy and pharmacokinetics for subcutaneous amivantamab combined with lazertinib compared to intravenous administration.

In part 2 of this video interview, Sam Liu, VP of marketing, Vivalink discusses the key differences between consumer- and medical-grade wearables and their uses in clinical settings.

New solution, CARA AI, will aid in the exploration of real-world data and leverage workflows such as imaging and cohort generation.

In part 1 of this video interview, Sam Liu, VP of marketing, Vivalink touches on concerns with data accuracy and security in bring-your-own-device models.

Lexicon will utilize Medidata’s decentralized clinical trial solutions to accelerate study of LX9211 in diabetic peripheral neuropathic pain.

Results showed median progression-free survival reached 12.6 months in patients with CLDN18.2 high or medium expression, including in patients with PD-L1 CPS<5.

New collaboration offers end-to-end solution, supplying and training sites on ophthalmic medical imaging equipment.

Expanded collaboration seeks to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases.

New agreement leverages Beaconcure’s technology to streamline review processes.

Newly published consensus statement outlines RCT questions ranked according to importance and feasibility.

ICON plc CEO Steve Cutler discussed how strategic partnerships are driving advancements in clinical trials.

Retrospective cohort study sought to identify similarities between response- and progression-based end points in clinical trials and weighted observational cohorts of patients.

In the fifth and final part of this video interview series, Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine and Steve Young, chief science officer, CluePoints look ahead to the future of risk-based quality management and what adoption will look like.

In part 4 of this video interview series, Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine and Steve Young, chief science officer, CluePoints touch on what risks companies leave themselves susceptible to without the adoption of risk-based approaches.

Expanded relationship will utilize Medidata’s artificial intelligence solutions.

In part 3 of this video interview series, Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine and Steve Young, chief science officer, CluePoints discuss what could be holding stakeholders back from adopting risk-based quality management.

Blockbuster cancer therapies failed to improve progression-free survival as combination.

In part 2 of this video interview series, Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine and Steve Young, chief science officer, CluePoints highlight what stood out to them from the results of a recent study on RBQM adoption.

In part 1 of this video interview series with Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine and Steve Young, chief science officer, CluePoints, Getz touches on the findings from a recent study on RBQM adoption.

A cohort study used county-level data on social determinants of health to examine their association with oncology study access.

Midpoint clinical trial data for Teal Health’s Teal Wand is promising after exceeding initial enrollment numbers in the last 6 months.

Phase Ia trial of VYN202, expected to begin this quarter, will enroll approximately 64 healthy participants.

Systematic review of over 300 randomized clinical trials sought to determine how often these values were overestimated in contemporary cardiovascular trials.

In the fourth and final part of this video interview with ACT editor Andy Studna, Rohit Nambisan, CEO & founder of Lokavant looks into the future of feasibility studies, the integration of AI, and how they are driving more personalized approaches.

In part 3 of this video interview with ACT editor Andy Studna, Rohit Nambisan, CEO & founder of Lokavant analyzes some of the most common mistakes he has seen stakeholders make in feasibility studies and how they can be addressed.

In part 2 of this video interview with ACT editor Andy Studna, Rohit Nambisan, CEO & founder of Lokavant touches on structuring feasibility studies and how they can make running a trial more efficient.